设为首页|加入收藏|英文版

总体介绍

首页 > 广东省中医药科学院 > 总体介绍

中医药防治乳腺病研究团队

2017/7/18 9:52:28字号:T|T

 

中医药防治乳腺病研究团队是在复兴中华医学的战略背景下,作为我院国家中医药管理局乳腺病重点建设专科的组成部分于2015年正式成立。团队充分结合中医药基础理论与现代分子医学体系,针对临床乳腺病学的难点和盲区进行探索性研究,以有效、客观和科学为宗旨,积极推进中医与西医、临床与基础、理论与产品之间的转化研究。主要目标是探讨乳腺癌应激生物行为学的调节机制和及相关靶点,并以此阐释中医治疗乳腺癌的理论和实践基础,筛选靶向应激的小分子调节剂,力争在中西医结合领域形成理论创新、技术创新、方法创新的研究成果。

With the overwhelming trend of developing traditional Chinese Medicine (TCM) worldwide, the integrative research laboratory of breast diseases prevention & treatment was established in 2015. As an important part of the key specialist construction project supported by SATCM (state administration of TCM), our laboratory aims to integrate TCM and modern molecular medicine pointing at the clinical difficult problems (cancer drug resistance, metastasis, prevention, etc), and to carry out translational study between TCM and western medicine, between clinical and basic research and between theory discovery and product commercialization with the criteria of efficacy, safety and high scientific value. The main research focus is to explore the stress-related signaling in breast cancer development, identify the potential therapeutic targets and screen bioactive stress modulating drugs from TCM. Our research will not only provide theoretical and laboratory evidence for integrative cancer treatment, but also generate creative technology & methodology for TCM research.

 

团队成员  Team Members

学术带头人Academic leaders



林毅,主任医师,教授,广州中医药大学主任导师。全国名中医,广州中医药大学附属广东省中医院一级教授,全国第二批、第四批继承老中医药专家学术经验指导老师,国家中医药管理局全国名老中医传承工作室名师,国家中医药管理局乳腺病重点专科学科带头人,从事中医、中西医结合乳腺病临床、教学和科研工作50余年,研究内环境因素对乳腺病发生发展的影响及机制,在全国具有鲜明的学术特点和重要的学术地位。  

Professor Lin Yi, chief physician, first-class professor in Guangzhou University of Chinese Medicine, national famous TCM expert, academic leader of state mammary diseases specialists. She devotes into breast research more than 50 years and has rich experience in dealing mammary inflammation, hyperplasia and breast cancer, etc. During her career life, she was awarded national health advanced worker twice and one national patent. Her main research focus on discovering novel factors influencing breast disease occurrence and prognosis from a unique perspective of internal environment.

 团队负责人 Principle Investigator:

王志宇,博士,研究员,中医药防治乳腺病研究团队负责人。主攻应激因素与乳腺癌发生发展及中医药防治。担任中华中医药学会乳腺病分会及广东省中医药学会乳腺病专业委员会委员,世界中医药学会联合会中药系统与工程分会常务理事。主持国家自然科学基金2项,广东省自然科学基金杰出青年项目1项,广州市珠江科技新星1项,香港卫生署基金项目等课题6项,经费300余万元,发表SCI论文30余篇,累积影响因子100余点,担任多种国际杂志编委及审稿专家。

Professor Wang Zhiyu, Ph.D, M.D., Principle investigator. His main research focuses on identification and characterization of stress-related targets in breast cancer development and TCM intervention. He served as a committee member of TCM science& technology committee affiliated to world federation of Chinese Medicine societies and mammary disease committee of Guangdong TCM association, etc. He successfully applied 6 grants including two NSFC projects, one Guangdong Natural Science Fund for Distinguished Scholar, one Pearl River Nova Program of Guangzhou, and one Hong Kong HMRF project, etc. The total funds reached over 3 million. He published over 30 articles indexed by SCI with a total impact factor over 100 points. Meanwhile, He served as editorial member or reviewer for a variety of peer-reviewed international journals.

客座教授及团队骨干  Team Core Members

客座教授

 

 

陈建萍 教授

香港大学

中医药防治乳腺癌的中西医结合转化研究

沈剑刚 教授

香港大学

肿瘤靶点鉴定及生物行为学研究

张奉学 教授

广州中医药大学

肿瘤免疫治疗与中医药防治转化研究

唐海林 副教授

中山大学

乳腺癌靶向治疗

王能   副教授

广州中医药大学

中草药抗肿瘤药理及分子靶点鉴定方法学研究;

王迪   副教授

吉林大学

中草药抗肿瘤药理及分子靶点鉴定方法学研究;

高磊   副教授

南方医科大学

肿瘤靶点鉴定及生物行为学研究

团队骨干

 

 

邓海霞 博士

中医药防治乳腺病研究团队

中医药防治乳腺癌的中西医结合转化研究

郑轶枫 博士

中医药防治乳腺病研究团队

肿瘤应激调控机制及靶标分子的鉴定

王胜奇 博士

中医药防治乳腺病研究团队

肿瘤应激调控机制及靶标分子的鉴定




团队主攻方向 Main Research Direction

(1) 肿瘤应激调控机制及靶标分子的鉴定;

Stress-related Mechanisms and Therapeutic Targets Involved in Cancer Development

肿瘤在从恶性转化到耐药转移的发展过程中,不断接受内源性和外源性的各种应激刺激,如代谢应激、氧化应激、内质网应激等等,正是应激性因素驱动了肿瘤的进化,鉴定并发现应激调控保护分子机制及靶向药物将会为有效干预肿瘤发生与转移提供特异而高效的突破口,为改善肿瘤预后提供新思路;


 

During the process from malignant transformation to advanced cancer drug resistance or metastasis, cancer cells have to adapt to multiple stress signal stimulus such as metabolism alteration, redox pressure and endoplasmic reticulum stress, etc. It is considered that stress signal might be the root for cancer evolution. Therefore, identification and characterization of stress-related mechanisms and targeting drugs will shed novel light for preventing cancer initiation and metastasis. 

(2)中草药抗肿瘤药理及分子靶点鉴定方法学研究;

Pharmacological Mechanisms of Anti-cancer Herbs and Development of Novel Target Identification System

中药由于药效成分复杂、分子机制不清,国际推广受到很大阻力,而传统的药效成份分析分离技术耗时耗力,急需开发新型技术鉴定药效成分及分子靶标。基于生物组学技术的发展,团队拟开发基于靶标蛋白与小分子化合物结合稳定性的磁力共沉淀技术构建新型药效成份鉴定系统。同时期望构建多靶点聚合芯片,采用分子动力学技术检测小分子化合物的直接靶标蛋白,提速中医药现代化、国际化进程;

   Due to the complex ingredients, unclear molecular mechanisms and the traditional time-consuming separation technique, the internalization of TCM faces a big challenge, it is necessary and urgent to develop novel techniques in identifying bioactive compounds and their molecular targets. With the development of omics study, our team has developed a target identification system based on drug-target affinity response to protease degradation. Meanwhile, we aim to establish a target-based chip to identify the potential phytochemical inhibitor from Chinese herbs by SPR technology. We believe the development of hi-technology of target identification will promote the modernization of TCM. 


(3) 中医药防治乳腺癌的中西医结合转化研究;

Translational Breast Cancer Research of Integrative Medicine

    中医药在肿瘤预防、改善肿瘤预后、减毒增效及提高生存质量方面具有鲜明特色,但面临标准不一、机制不清、临床证据不足等问题,从中医药系统循证评价、质量标准统一、临床前药效药理研究、毒理研究、临床试验及二次优化开发等角度进行中西医结合研究将为中医药临床精准干预乳腺癌防治提供有力证明;

TCM has a unique priority on cancer prevention, survival prolongation, detoxification and life quality improvement, but there exist huge difficulties in criteria standardization, mechanism clarification and large-scale clinical trials. It is necessary to promote integrative study from the perspectives of meta-analysis, chemical quality standardization, pre-clinical efficacy and toxicity study, clinical trial and secondary optimizing research, the results will provide convincing evidence for TCM precise intervention in clinical settings.  
 
 

主要学术及研究成果                       



 承担的主要研究课题:

 

课题名称

任务来源

级别

负责人

经费

(万元)

Caveolin-1介导乳腺癌干细胞化疗抵抗和干性维持的作用和分子机制

国家自然科学基金委员会

国家级

王志宇

23

基于肿瘤干细胞免疫微环境TAMs/CXCL-1通路探讨消癖颗粒预防乳腺癌的分子机制和物质基础

国家自然科学基金委员会

国家级

王志宇

74

Caveolin-1抑制肿瘤干细胞Warburg效应对乳腺癌的预防作用及分子机制研究

珠江科技新星

省部级

王志宇

60

内质网应激蛋白GRP78介导乳腺癌干细胞化疗抵抗的作用机制及其小分子抑制剂异甘草素的开发研究

广东省杰出青年基金

省部级

王志宇

100

基于肿瘤干细胞代谢特征探讨消癖颗粒调控Caveolin-1预防乳腺癌的分子机制和物质基础

高水平大学建设项目

院校级

王志宇

20

Exploration of dietary compound isoliquiritigenin in chemosensitizing  breast cancer stem cells by targeting aberrant β-catenin signalling 

香港卫生署

国际级

王志宇

 

75.836

基于“内环境平衡”探索中医药干预乳腺癌的研究

广东省中医药局

省部级

林毅

50

林毅名医工作室建设项目

国家中医药管理局

 省部级

司徒红林

50

基于“邪之所凑,其气必虚”探讨乳腺癌转移前VEGFR1+HP

变化及复康灵胶囊对其影响

广东省中医院院内专项

省部级

陈前军

25


发表的主要学术论文:

 

论文

期刊

影响

因子

第一

作者

通讯作者

The inflammasome: an emerging therapeutic target for cancer prevention

Oncotarget, 2016

5.008

王志宇

王志宇

Broadleaf Mahonia attenuates granulomatous lobular mastitis-associated inflammation by inhibiting CCL-5 expression in macrophages

International Jouranl of Molecular Medicine, 2017

2.348

王志宇

王志宇

Caveolin-1, a stress-related oncotarget, in drug ressitance

Oncotarget, 2015

6.359

王志宇

王志宇

Targeting AMPK signaling pathway to overcome drug resistance for cancer therapy

Current Drug Targets, 2015

3.597

王志宇

王志宇

Dietary Compound Isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF-1 demethylation

Oncotarget, 2015

 

6.359

王志宇

陈建萍

Caveolin-1 mediates chemoresistance of breast cancer stem cells via β-catenin/ABCG2 signaling pathway

Carcinogenesis, 2014

5.266

王志宇

陈建萍

MicroRNA-25 regulates autophagy associated with chemoresistance of breast cancer cells: a process modulated by natural autophagy inducer isoliquiritigenin

Oncotarget, 2014

6.627

王志宇

陈建萍

Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling

Carcinogenesis, 2014

5.266

王志宇

陈建萍

Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells

Oncogene, 2010

7.414

邓海霞

宋尔卫


Contact information:

Tel: +86-18819480766;

Email: wangzhiyu@gzucm.edu.cn; wangzhiyu976@126.com;

 









首页|网站地图|法律申明|友情链接|招聘信息|供应商管理|名老中医学术交流|中医健康管理|中医医案管理 |知识管理|在线考试